The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
 
Elena Elimova
Employment - Merck (I)
Consulting or Advisory Role - Adaptimmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca Canada (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Zymeworks (Inst)
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Arcus Biosciences; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Insys Therapeutics; Merck; Novartis; SERVIER; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); BioTheryX (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CicloMed (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Incyte (Inst); Novartis (Inst); TG Therapeutics (Inst); Vincerx Pharma (Inst)
 
Crystal S. Denlinger
Consulting or Advisory Role - BeiGene; Bristol Myers Squibb; Exelixis; Merck; Zymeworks
Research Funding - Agios (Inst); Amgen (Inst); Array BioPharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genmab (Inst); Macrogenics (Inst); MedImmune (Inst); Sanofi (Inst); Zymeworks (Inst)
 
Syma Iqbal
Honoraria - BeiGene
Consulting or Advisory Role - AstraZeneca; BMS; BMS; Daiichi Sankyo/Astra Zeneca; Merck
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
YEUL HONG Hong Kim
Stock and Other Ownership Interests - OncoMaster
Research Funding - Korea Astellas (Inst); Macrogenics (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Zymeworks (Inst)
 
Keun-Wook Lee
Honoraria - Boryung; JW Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; Sanofi/Aventis; Vifor Pharma
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Bruce Lin
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Exelixis; Pfizer; QED Therapeutics
Research Funding - Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Incyte (Inst); Merck (Inst); Nucana (Inst); Sillajen (Inst); Zymeworks (Inst)
 
Rutika Mehta
Honoraria - ASCO; Bristol-Myers Squibb
Consulting or Advisory Role - Astellas Pharma; AVEO (I); BostonGene; Bristol-Myers Squibb; Bristol-Myers Squibb (I); EMD Serono (I); Guardant Health; Immunomedics (I); Lilly; NCCN/Pfizer (I); Seagen (I)
Speakers' Bureau - Daiichi Sankyo; Gilead Sciences (I); Natera
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Eutilex; Indivumed; LG Chem; MSD Oncology; Sanofi
Speakers' Bureau - Amgen; BMS/Ono; Eisai; Lilly; MSD Oncology
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Lilly; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Yong Mi Soel
No Relationships to Disclose
 
Lisa Boyken
Employment - Lyell Immunopharma (I); Outpace Bio (I); Zymeworks
Leadership - Outpace Bio (I)
Stock and Other Ownership Interests - Lyell Immunopharma (I); Outpace Bio (I); Zymeworks
Patents, Royalties, Other Intellectual Property - Lyell Immunopharma (I); Outpace Bio (I); University of Washington (I)
 
Jonathan E. Grim
Employment - Zymeworks
Stock and Other Ownership Interests - Medtronic (I); Vanguard Funds; Zymeworks
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Apexigen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; I-Mab; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Adaptimmune (Inst); Arog (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CARsgen Therapeutics (Inst); Daiichi Sankyo (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Pieris Pharmaceuticals